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Editorial

Kinase independent oncogenic cyclin D1
Mathew C. Casimiro, Andrew Arnold, and Richard G. Pestell

cyclin D1KE induced aneuploidy to a similar degree
compared to control cells. Cyclin D1KE induced
aneuploidy to a similar extent in absence or presence of
cdk4/6 agonist. Crucially, sustained transgenic
expression of cyclin D1KE induced mammary
adenocarcinoma with similar kinetics to that of a cyclin
D1WT transgene [1]. ChIP-Seq studies demonstrated
recruitment in the context of local chromatin of either
cyclin D1KE or cyclin D1WT to the genes governing
CIN. Thus, cdk-activating function of cyclin D1 was not
necessary for the induction of either chromosomal
instability or murine mammary tumorigenesis.
Understanding the different contexts and causes of
cyclin D1 overexpression in breast cancer may be
exceedingly important in considering its tumorigenic
mechanisms. In this regard cyclin D1 knockout mice are
resistant to breast cancer, however recent studies have
shown that cyclin D1 genetic deletion abrogates the
formation of progenitor cells that in turn give rise to
cancer. Cyclin D1-/-KE rescue mice are resistant to ErbB2
mediated tumorigenesis [4]. Elegant studies by Hinds’
group identified a progenitor population of cells in
mouse mammary gland (parity-identified mammary
cells: PI-MEC) that require cyclin D1 kinase activity for
self renewal and differentiation [5]. An analysis on the
cyclin D1-/- KE rescue confirmed that the resistance to
ErbB2 driven tumorigenesis is linked to near total
absence of the PI-MEC, making those progenitor cells
the likely target for ErbB2 induced tumorigenesis.
Cyclin D1 kinase activity is therefore required for
mammary progenitor cells self-renewal and activity,
highlighting this key role for cyclin D1 during
development. In contrast, our recent study of mice
bearing the MMTV-cyclin D1KE transgene addressed
whether cyclin D1 overexpression can directly induce
mammary tumorigenesis in a kinase independent
manner, with a robust answer of ‘yes’.
The MMTV-ErbB2 and MMTV-cyclin D1 models are
distinct. MMTV-ErbB2 induced mouse tumorigenesis
represents a good model for human breast cancers with
HER2 amplification, and the role of cyclinD1 when
expressed secondary/downstream to other events (like
ErbB2 amplification) may well be kinase dependent. In
contrast, MMTV-cyclin D1 mice better represent the
sizeable group of cyclin D1-amplified cancers, induced
by primary, driver-level overexpression of the cyclin D1

Strong evidence implicates cyclin D1 overexpression as
a driving force in breast cancer and many other types of
human tumors. Cyclin D1 overexpression is found in up
to 50% of human breast cancers, and the pattern of
cyclin D1 overexpression in tissues along the spectrum
from normal epithelium to invasive breast cancer
suggests its involvement in the earliest stages of
mammary carcinogenesis. The importance of cyclin D1
as a driver oncogene is reinforced by the frequent clonal
selection of cyclin D1 gene amplification, found in 1520% of breast cancers, associated with poor prognosis,
and by the fact that tissue-specific overexpression of
cyclin D1 in transgenic mice results in mammary
hyperplasia and adenocarcinoma [1]. However, the
precise mechanisms through which cyclin D1
overexpression contributes to breast tumorigenesis have
been controversial. Specifically, while cyclin D1's role
in the pathogenesis of breast cancer may well involve,
at least in part, the well-established binding/activation
of its catalytic partner kinases CDK4/6, with subsequent
hyperphosphorylation of pRB and G1-S cell cycle
transition, several lines of evidence have suggested that
cyclin D1, especially when overexpressed in the setting
of cancer, may also act through other, CDKindependent,
mechanisms.
These
alternative
mechanisms of cyclin D1 action carry tremendous
potential significance, for example in the rational
targeting of new therapeutic agents. Our recent study
[2] is perhaps the most direct test of this hypothesis
performed in a highly relevant in vivo model system.
The induction of chromosomal instability is known to
promote genetic rearrangements, tumorigenesis and the
molecular genetic chaos associated with poor outcome
cancers. The early drivers to chromosomal instability
are poorly understood. Our recent studies showed that
modest overexpression of cyclin D1 is sufficient for the
induction of chromosomal instability within 3 cell
divisions, both in vitro and in vivo. Furthermore we
showed the induction of CIN occurred independently of
the kinase function. In ChIP-Seq cyclin D1 associates
with genes governing chromosomal instability (CIN)
[3]. Using a kinase dead mutant of cyclin D1 (cyclin
D1KE ) we showed cyclin D1 induced - mitotic spindle
architecture changes of chromosomal instability and
supernumerary centrosomes aneuploidy and other
features of CIN. In cdk4/6-/- 3T3 cells cyclin D1WT and
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oncogene. Cyclin D1 oncogene activation is a prevalent
molecular driver of human cancer, playing key roles in
breast, squamous cell, esophageal carcinoma, mantle
cell lymphoma, multiple myeloma, and many other
devastating human malignancies. Our novel in vivo
evidence shows this mechanism can be kinaseindependent, counter to the generally accepted “CDKcentric” paradigm of the tumorigenic activity of cyclin
D1. In the clinical realm, these observations suggest that
some therapeutic agents now approved or in
development, most notably CDK4/6 inhibitors, will
have limited efficacy in cyclin D1-amplified cancers
since they target only the kinase partners of cyclin D1.
Thus, without minimizing the improved progressionfree survival associated with pharmacologic CDK4/6
inhibition in ER+ breast cancers, our data suggest that
in the subset of tumors with, and potentially addicted to,
cyclin D1 amplification or rearrangement, a more
effective path to impactful tumor shrinkage as opposed
to slowing of growth will be to develop agents that
target cyclin D1 directly. In summary, while cyclin D1
kinase activity is important in tumorigenesis, additional
distinct kinase-independent mechanisms, including
induction of chromosomal instability, are helping drive
some tumors and attempts to exploit this finding using
precision medicine should be encouraged.
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